IDH Results Presentation
April 2023
Table of
Contents
IDH At a Glance
FY 2023 Results Overview
Key Investment Highlights
Our Market
Our Business Model
Financial Position and Performance
Growth Strategies
Governance
Who We Are (I/II)
Integrated Diagnostics Holding is a leading, fully-integrated provider of high-quality medical diagnostic services with a
footprint spanning Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia
An integrated diagnostics provider… | |||||||||||||||||||||
Pathology | Radiology | ||||||||||||||||||||
Immunology | Microbiology | Haematology | Endocrinology | ||||||||||||||||||
PET-CT | Mammography | Electromyography | |||||||||||||||||||
MRI | Ultrasound | Electroencephalography | |||||||||||||||||||
Clinical | Molecular | Parasitology | Histopathology | Genetics | CT | X-Ray | Electrocardiogram | ||||||||||||||
Chemistry | Biology | ||||||||||||||||||||
…with a suite of internationally-accredited,market-leading brands | |||||||||||||||
Our Brands | Our Accreditations | ||||||||||||||
21% | |||||||||||||||
Shareholding | 52% | ||||||||||||||
Structure | |||||||||||||||
27% | |||||||||||||||
Hena Holdings Ltd | Actis IDH B.V. | Free Float | |||||||||||||
3 INTEGRATED DIAGNOSTICS HOLDINGS
Who We Are (II/II)
The Company's reach, scale, and service quality are unmatched across its markets of operation
Track Record
+40 years
First lab established in 1979
Patients
c.10 MN
Per year
Tests
c.30 MN
Per year
Market Reach
Over 601 Branches
As at 31 December 2023
Accreditations
CAP & ACR
Accredited lab and scan
Test Portfolio
+3,000
Tests
Dual-listing
LSE in 2015 | EGX in 2021
Nigeria
Sustainable Growth
19%
Revenue CAGR 2015-23
Jordan
Egypt
Saudi
Arabia
Sudan
4 INTEGRATED DIAGNOSTICS HOLDINGS
Our Service Segments
IDH's pathology offering currently contributes the lion share of revenue and patients. The Company's radiology services
are quickly gaining momentum with their contribution to IDH's top-line doubling in the last twelve months
Pathology - 94% of Revenues1 | Radiology - 6% of Revenues1,2 | ||||||||||||||||
Through IDH's brands, the Group offers over 3,000 internationally | IDH offers a vast array of radiology services through Al Borg Scan in Egypt | ||||||||||||||||
accredited pathology tests ranging from basic blood glucose tests for | and Echo-Lab in Nigeria. Al Borg Scan is also the sole radiology provider | ||||||||||||||||
diabetes to advanced molecular testing for genetic disorders. | in Africa boasting the prestigious American College of Radiology (ACR) | ||||||||||||||||
accreditation, a testament to the high-quality services delivered by the | |||||||||||||||||
venture. | |||||||||||||||||
582 | 1979 | c. 10mn | c. 30mn | 19 | 2018 | c. 1.2mn | c. 1.9mn | ||||||||||
Pathology | Year | Patients served | Tests performed | Radiology | Year | Patients served | Scans conduced | ||||||||||
branches | launched | each year | each year | branches | launched | since inception | since inception | ||||||||||
Competitive Strengths | Competitive Strengths and Strategic Advantages |
Visibility and | Scalable | Diversify and | Deliver on one- | ||||||||||||||||||
Track | Reach and | Established | High-fragment | ||||||||||||||||||
Record | scale across | Reputation | Business | platform to | and fast- | Grow Revenue | stop-shop | ||||||||||||||
attractive | Model | build on | growing market | Streams | vision | ||||||||||||||||
markets | |||||||||||||||||||||
An integrated offering catering to patients' evolving needs
- Share of IDH FY 2023 consolidated revenue.
- Radiology revenues are calculated as Echo-Lab (IDH's Nigerian subsidiary) revenues plus Al-Borg Scan revenues (Egypt's radiology business).
5 INTEGRATED DIAGNOSTICS HOLDINGS
Our Geographies
IDH currently operates the largest branch network amongst private providers in Egypt and boasts an established
presence in four key markets in the Middle East and Africa
Egypt | Jordan | Nigeria | Sudan | |||
1979 | 544 | 2011 | 27 | 2018 | 12 | 2011 | 182 | ||||||||||||
First began | Branches (51% in | Acquisition | Branches | Acquisition of Echo- | Branches | Acquisition of Ultra | Branches | ||||||||||||
operations | Cairo Region) | of Biolab | Lab | Lab | |||||||||||||||
#1 | 83% | #1 | 15% | Top 5 | 2% | #1 | 0.3% | ||||||||||||
Market Ranking1 (#1 | Share of consolidated | Market Ranking1 | Share of consolidated | Market Ranking | Share of consolidated | Market Ranking1 | Share of consolidated | ||||||||||||
in Corporate | revenues in FY 2023 | revenues in FY 2023 | revenues in FY 2023 | revenues in FY 2023 | |||||||||||||||
Insurance Sector) | |||||||||||||||||||
8.0 mn | 33.4 mn | 372 k | 2.4 mn | 132 k | 266 k | 14 k | 40 k | ||||||||||||
Patients served | Tests performed | Patients served | Tests performed | Patients served | Tests performed | Patients served | Tests performed | ||||||||||||
in FY 2023 | in FY 2023 | in FY 2023 | in FY 2023 | in FY 2023 | in FY 2023 | in FY 2023 | in FY 2023 | ||||||||||||
- Market ranking amongst private players in each respective country.
- 17 of IDH's branches in Sudan have been closed due to the ongoing conflict in the country.
6 INTEGRATED DIAGNOSTICS HOLDINGS
Our Patients
IDH serves two principal types of patients: contract and walk-in
Around 70% of total revenue generated across the two segments is paid in cash
Contract Patients1 | Walk-In Patients | |
IDH's contract clients include institutions who enter into one-year renewable contracts at agreed rates per-testand on a per-clientbasis. Around 40% of the revenue generated by the segment is paid in cash. IDH's corporate clients roster currently features institutions such as:
- Unions
- Syndicates
- Private and public insurance companies
- Banks and corporations
- Public institutions
- Government insurance
IDH's walk-in clients, also referred to as "self-payers",pay out of pocket for diagnostic tests and other services.
Contribution to IDH Revenues (FY 2023)
36% EGP
4,123
mn 64%
Contract Revenues | Walk-in Revenues | ||
1 Testing prices at the contract segment are generally lower than those of the walk-in segment and are not pre-set as with walk-in testing
7 INTEGRATED DIAGNOSTICS HOLDINGS
Patient Split by Segment (FY 2023)
21%
8.5 mn
patients
79%
Contract Patients | Walk-in Patients | |
IDH Post Covid-19 : A new chapter (I/II)
During the Covid-19 era, IDH successfully transformed its business, expanding its service offering and delivery
capabilities, and setting the foundation for a new chapter of sustainable growth, testament to its business agility and
resilience
Test Offering and Delivery | Reach and Visibility | Agility | ||
Conventional Business Back to Pre- | Ramped up | Ramped Up House Call | Growing Physical | Rapid Service Offering Adaptation |
Covid Levels | House Call Services | Capacity | Presence |
+89%
Growth in conventional test1,2 revenue vs FY 2019
Frontline Role in Fight Against
Covid-19
9.0 mn
Covid tests performed in
Egypt and Jordan
(2020-2022)
16%
House call contribution to Egypt revenues in FY 2023 (exceeding pre-pandemic averages of 10-11%)
Al-Borg Scan
Expansion
7
Operational Branches as at
31 December 2023 (fastest
growing radiology brand in
Egypt)
up to 5k | +49 | #1 | #1 | #1 | ||||||||
House call visits per day, with | New branches opened | in PCR testing in | leading PCR testing | for house call | ||||||||
over 10k calls answered daily | during the last 12-month | Egypt and first to | provider in Jordan | volumes in Egypt | ||||||||
period | offer QR codes | |||||||||||
New Patient | Largest Private Provider | Ample Capacity for Growth | ||||||||||
Segments | in Egypt | |||||||||||
c. 5 mn | 601 | 5-7 yrs. | 40% | |||||||||
New patients acquired | Operational Branches as at | Average contract tenors for Spare processing capacity in | ||||||||||
during Covid-19-pandemic | 31 December 2023 (544 | equipment | Mega Lab | |||||||||
(2020-2022) | branches in Egypt) | |||||||||||
A patient-centric business geared for long-term, sustainable growth
- Conventional tests refer to IDH's service offering excluding all Covid-19-related testing performed during the period.
- 2019 tests exclude contributions from the 100 million lives campaign.
8 INTEGRATED DIAGNOSTICS HOLDINGS
IDH Post Covid-19: A new chapter (II/II)
During the Covid-19 era, IDH successfully transformed its business, expanding its service offering and delivery
capabilities, and setting the foundation for a new chapter of sustainable growth, testament to its business agility and
resilience
Improved Efficiency | Long-term Relationships |
Decreased Turnaround Times and Improved Patient Satisfaction
over 80% | max 24hr | |
Net Promoter Score (NPS) | Turn-around time | |
Expanded Digital Capabilities
over 5k Chatbot conv/day | Convenient Payments | |||
Diversifying patient touch-points | Leveraging expanded digital presence | |||
Revamped Loyalty Programme
In partnership with leading loyalty solutions provider to retain existing/new
patients acquired in 2022
Expanded Cross-selling Capabilities
Monitoring patient records and disease cycles to provide tailored services
and increase cross-selling
Marketing Strategy
Visibility bolstered by additional marketing efforts throughout the year including
launch of new IDH branded cars as well as greater social media presence
A patient-centric business geared for long-term, sustainable growth
1 Convention tests refers to IDH's service offering excluding all Covid-19-related testing performed during the period.
9 INTEGRATED DIAGNOSTICS HOLDINGS
FY 2023
Results
Overview
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
IDH - Integrated Diagnostics Holdings plc published this content on 17 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2024 14:37:02 UTC.